Login to Your Account

Financings Roundup

Metabolic Solutions Development Raises $23.5M in Series D Round

By Catherine Shaffer

Friday, October 22, 2010

No Abstract

BioWorld Today Contributing Writer

Kalamazoo, Mich.-based Metabolic Solutions Development Co. (MSDC) will use $23.5 million in proceeds from a Series D financing round to push its Type II diabetes drug candidate (MSDC-0160) through Phase IIB trials. Michigan-based Hopen Life Sciences led the investment with follow-on support from Southwest Michigan First Life Science Fund. MSDC has defied a persistent downward trend in the hard-hit Michigan economy by raising nearly $50 million since it was founded in 2006.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription